Offered under Bolar Exemption
Bachem Regulatory Documentation
LY-135252; LY-139602; LY-139603; Tomoxetine Hydrochloride;
(R)-(-)-N-Methyl-3-(o-tolyloxy)-3-phenylpropylamine · HCl;
(R)-(-)-N-Methyl-γ-(2-methylphenoxy)-benzenepropanamine · HCl
Fields of Application
Attention deficit hyperactivity disorder (ADHD)
Atomoxetine Hydrochloride is a selective noradrenaline (norepinephrine) re-uptake inhibitor. Atomoxetine Hydrochloride is a non-stimulant drug approved for the treatment of attention deficit hyperactivity disorder (ADHD).
This product is offered and sold solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use or sale of drugs (the “Bolar Exemption”). Bachem cannot be made liable for any infringement of intellectual property rights. It is the sole and only responsibility of the purchaser or user of this product to comply with the relevant national rules and regulations.